Personalis’ (PSNL) “Buy” Rating Reaffirmed at HC Wainwright

Personalis (NASDAQ:PSNL)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $8.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 88.68% from the company’s previous close.

Several other analysts have also recently issued reports on PSNL. Lake Street Capital boosted their price objective on shares of Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Needham & Company LLC lowered their price target on Personalis from $7.25 to $7.00 and set a “buy” rating for the company in a research report on Friday.

Personalis Trading Down 5.4 %

Shares of NASDAQ:PSNL opened at $4.24 on Friday. The firm has a market cap of $299.55 million, a price-to-earnings ratio of -2.52 and a beta of 1.73. The stock’s 50-day moving average price is $5.43 and its two-hundred day moving average price is $5.04. Personalis has a 12-month low of $1.13 and a 12-month high of $7.20.

Personalis (NASDAQ:PSNL) last released its earnings results on Thursday, February 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.09. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. As a group, research analysts forecast that Personalis will post -1.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Personalis

Several large investors have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Personalis during the 4th quarter valued at $28,000. JPMorgan Chase & Co. increased its holdings in Personalis by 2,827.0% in the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock valued at $34,000 after purchasing an additional 5,654 shares in the last quarter. Olympiad Research LP purchased a new position in Personalis in the fourth quarter valued at about $59,000. Alpine Global Management LLC acquired a new position in shares of Personalis during the fourth quarter worth about $60,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Personalis in the fourth quarter worth about $63,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.